# Oncolytics Biotech

Source: https://onco.cc/companies/oncolytics-biotech/  
OnCo record `oncolytics-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Oncolytics Biotech is a United States-based biotechnology company running 3 late-stage cancer trials of Trifluridine Tipiracil in colorectal cancer, HR-positive / HER2-negative breast cancer and anal cancer.

## Summary

Oncolytics Biotech, based in San Diego, the United States, is a biotechnology company. Oncolytics Biotech develops immunotherapies for gastrointestinal and other cancers, centred on pelareorep, an investigational double-stranded RNA immunotherapeutic agent. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Trifluridine Tipiracil in colorectal cancer, HR-positive / HER2-negative breast cancer, anal cancer and pancreatic ductal adenocarcinoma. The largest, NCT07280377 (A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab), plans to enrol 122 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor
- HQ: San Diego
- Type: biotech
- Website: https://www.oncolyticsbiotech.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Oncolytics_Biotech
- Official website: https://www.oncolyticsbiotech.com
- ClinicalTrials.gov: trials led by Oncolytics Biotech: https://clinicaltrials.gov/search?lead=Oncolytics%20Biotech

## Connected records

- cancers: [Anal cancer (squamous cell carcinoma)](https://onco.cc/cancers/anal/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- trials: [A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab](https://onco.cc/trials/nct07280377/), [FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer](https://onco.cc/trials/nct07446322/)

---
JSON: https://onco.cc/api/v1/entities/oncolytics-biotech.json